Literature DB >> 16782309

A ketogenic diet and diallyl sulfide do not elevate afterdischarge thresholds in adult kindled rats.

Kirk Nylen1, Sergei S Likhodii, Kathryn M Hum, W M Burnham.   

Abstract

INTRODUCTION: Acetone has been shown to have broad-spectrum anticonvulsant actions in animal seizure models and has been hypothesized to play a role in the anticonvulsant mechanism of the ketogenic diet (KD). The present study examined the ability of a KD to elevate amygdaloid afterdischarge thresholds (ADT) in fully kindled rats. The effects of the KD were studied in the presence and absence of diallyl sulfide (DAS), an inhibitor of acetone metabolism.
METHODS: Twenty-four adult male rats were kindled to 30 stage 5 seizures. Afterdischarge thresholds (ADT) were determined. Subjects were then administered one of the following diets: (1) KD+V (vehicle; KD+V); (2) KD+DAS; (3) control diet+V (CD+V); (4) CD+DAS. They were stimulated every second day. Blood sampling was performed every second day--on non-stimulating days--to determine levels of glucose, beta-hydroxybutyrate, acetoacetate, and acetone. After 20 days, ADTs were re-determined.
RESULTS: Blood acetone concentrations were significantly higher in the KD+DAS group as compared to the other groups, although they did not reach "therapeutic levels". None of the treatments, however, elevated ADTs.
CONCLUSIONS: The KD was unable to elevate amygdaloid ADTs in fully kindled rats. Although subjects in the KD+DAS group achieved significant elevations of blood acetone, these concentrations (e.g. 0.2 mM) were much lower than those (>2.0 mM) previously shown to confer anticonvulsant activity. There appears to be large difference between humans and rats in their ability to produce elevated blood acetone levels on the KD. These data suggest that adult rats are not ideal subjects for modeling the anticonvulsant actions of the KD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782309     DOI: 10.1016/j.eplepsyres.2006.05.008

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  5 in total

Review 1.  Ketone bodies in epilepsy.

Authors:  Melanie A McNally; Adam L Hartman
Journal:  J Neurochem       Date:  2012-02-07       Impact factor: 5.372

Review 2.  What constitutes a relevant animal model of the ketogenic diet?

Authors:  Gregory L Holmes
Journal:  Epilepsia       Date:  2008-11       Impact factor: 5.864

3.  A ketogenic diet rescues the murine succinic semialdehyde dehydrogenase deficient phenotype.

Authors:  Kirk Nylen; Jose Luis Perez Velazquez; Sergei S Likhodii; Miguel A Cortez; Lily Shen; Yevgen Leshchenko; Khosrow Adeli; K Michael Gibson; W M Burnham; O Carter Snead
Journal:  Exp Neurol       Date:  2007-11-29       Impact factor: 5.330

Review 4.  The neuropharmacology of the ketogenic diet.

Authors:  Adam L Hartman; Maciej Gasior; Eileen P G Vining; Michael A Rogawski
Journal:  Pediatr Neurol       Date:  2007-05       Impact factor: 3.372

Review 5.  Neuroactive peptides as putative mediators of antiepileptic ketogenic diets.

Authors:  Carmela Giordano; Maddalena Marchiò; Elena Timofeeva; Giuseppe Biagini
Journal:  Front Neurol       Date:  2014-04-29       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.